CF PharmTech, Inc. (HKG:2652)

Market Cap	14.21B
Revenue (ttm)	647.51M +1,338.4%
Net Income	29.75M
EPS	0.08
Shares Out	411.75M
PE Ratio	477.71
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	134,500
Average Volume	172,690
Open	35.28
Previous Close	35.28
Day's Range	34.52 - 35.28
52-Week Range	27.20 - 48.80
Beta	n/a
RSI	51.79
Earnings Date	n/a

About CF PharmTech

CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs in the field of respiratory diseases in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment o...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 574
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2652

Financial Performance

In 2024, CF PharmTech's revenue was 607.75 million, an increase of 9.23% compared to the previous year's 556.42 million. Earnings were 21.09 million, a decrease of -33.53%.

Financial numbers in CNY